RTP Mobile Logo
Year in Review: On Demand — Significance and Relevance of Recent Data Sets and Publications in the Management of Breast Cancer
Released September 2018

Featuring key slides from the most important recent breast cancer presentations and publications and a video interview with Dr Hope S Rugo. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare professionals involved in the treatment of breast cancer.

    Breast cancer remains the most frequently diagnosed cancer in women, and in 2018 in the United States alone the disease will culminate in an estimated 268,670 new cases and 41,400 deaths. Although the diagnosis and treatment of breast cancer remain, in many ways, more advanced than in other solid tumors, challenging issues in the basic management of this disease continue to require refinement. Increasingly, an emphasis is being placed on a “personalized medicine” approach that promises to more effectively identify specific treatments that will benefit individuals based on patient- and disease-related characteristics. In conjunction with this approach, researchers are developing novel agents and immunotherapeutic strategies with the aim of enhancing the efficacy of existing treatments and overcoming resistance or restoring sensitivity to endocrine therapy, chemotherapy or biologic agents. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances.

    This special CME activity aims to bridge the gap between research and patient care by presenting a one-on-one discussion with leading breast cancer investigator Dr Hope S Rugo reviewing the year’s most important presentations and publications and summarizing their potential impact on current and future treatment algorithms.


    • Discuss the clinical relevance of recent pivotal breast cancer research results, as published in peer-reviewed journals and/or presented at major oncology conferences.
    • Consider published data to guide the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with hormone receptor-positive breast cancer in the neoadjuvant, adjuvant and extended-adjuvant settings.
    • Implement a long-term clinical plan for the management of metastatic HER2-positive breast cancer.
    • Develop an evidence-based algorithm for the treatment of hormone-sensitive advanced breast cancer, including the use of endocrine, biologic and chemotherapeutic agents.
    • Recall emerging efficacy and safety data with the use of PARP inhibitors in patients with metastatic breast cancer harboring a germline BRCA mutation, and consider the potential diagnostic and therapeutic implications of these findings on protocol and off-protocol care.
    • Appraise the rationale for and clinical data with investigational anti-PD-1/PD-L1 antibodies in patients with metastatic breast cancer.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials evaluating other novel therapeutic agents and strategies.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of slide and video components.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Hope S Rugo, MD
    Professor of Medicine
    Director, Breast Oncology and Clinical Trials Education
    University of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California

    Contracted Research: Eisai Inc, Genentech, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Plexxikon Inc, Roche Laboratories Inc; Paid Travel: Lilly, Mylan NV, Puma Biotechnology Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Lilly, Merck, Novartis and Puma Biotechnology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: September 2018
    Expiration date: September 2019

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

CDK4/6 Inhibitors in the Treatment of ER-Positive, HER2-Negative Breast Cancer (BC)

mTOR Inhibitors and Antiandrogens for ER-Positive BC

Adjuvant Therapy for BC

PARP Inhibitors for Advanced Disease

Role of Immune Checkpoint Inhibitors

Select Publications

Slide Presentation